MeiraGTx signs up to $375 million Oberland royalty financing, repays Perceptive notes
On June 30, 2026, MeiraGTx entered a royalty note purchase agreement with funds affiliated with Oberland Capital for up to $375 million, secured by company assets and tied to capped royalties on three gene therapy products. The company also agreed to sell 950,570 shares at $10.52 for about $10.0 million and fully redeemed its Perceptive credit notes on the same day. The royalty obligation and asset security add long-term commitments for shareholders, though the funding is non-dilutive apart from the small equity sale.
Key points
- Initial purchase of $100 million on June 30, 2026, with a second purchase of $25 million scheduled for July 17, 2026
- Revenue Payments equal to 1.95% of global net sales of AAV-AIPL1, AAV-hAQP1 and bota-vec, subject to a cap and payable after marketing approval
- Sale of 950,570 shares at $10.52 per share for about $10.0 million, with closing on July 17, 2026
- Full redemption of Perceptive notes on June 30, 2026, with no early termination penalties
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.